Home World News Potential of NOTCH1 Mutation to Predict Anti-PD1 Treatment Outcomes in Patients with... World News Potential of NOTCH1 Mutation to Predict Anti-PD1 Treatment Outcomes in Patients with Oesophageal Squamous Cell Cancer By Ogkologos - April 23, 2025 900 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a biomarker analysis from the RATIONALE-302 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR FDA Grants Accelerated Approval to Tepotinib for Metastatic NSCLC February 5, 2021 Adjuvant Everolimus Does Not Improve Recurrence-Free Survival Among Patients with Renal... August 9, 2023 Feasibility and Preliminary Efficacy Results of the Beat AML Study October 28, 2020 “Scars are Tattoos with Better Stories” July 21, 2021 Load more HOT NEWS Identification of Potential Biomarkers for Clinical Benefit Following Dual Neoadjuvant Anti-HER2... EMA Recommends Extension of Therapeutic Indications for Cetuximab Encorafenib, Cetuximab Combination Approved for Metastatic Colorectal Cancer FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer
